-
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
Wednesday, August 21, 2024 - 8:51am | 655The rivalry between Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments. Novo Nordisk & Eli Lilly – Expanding Beyond...
-
Gilead, Pfizer, Eli Lilly CEOs On COVID-19 Treatments, Vaccine Development
Monday, September 14, 2020 - 4:23pm | 742Major coronavirus treatments and vaccine maker executives were interviewed on CNBC Monday to discuss their company's progress in the battle against the disease. Gilead CEO On Remdesivir: Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir received an emergency use authorization designation in...
-
Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy'
Monday, June 1, 2020 - 3:40pm | 448Drugmaker Eli Lilly And Co (NYSE: LLY) started a human study of a potential antibody treatment for COVID-19 patients, and CEO David Ricks said on Fox Business that it is the first of its kind. Lilly's Brand New Medicine Eli Lilly's medicine to treat COVID-19 patients is the first...
-
Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin
Wednesday, December 18, 2019 - 12:07pm | 756Eli Lilly And Co (NYSE: LLY) CEO David Ricks said Tuesday that U.S. Sen. Elizabeth Warren’s criticism of the cost of the drugmaker's insulin is “nonsense.” Warren Says Eli Lilly Broke Promise On Insulin In a Monday Facebook post, the Democratic presidential candidate denounced...
-
Eli Lilly CEO Calls For Uniform Prices, Better Use Of Technology In Health Care
Thursday, June 7, 2018 - 4:24pm | 1228The American health care system is an unsustainable, half-century-old design that engages in price discrimination and has failed to employ technology to its potential to lower costs and expand access, Eli Lilly And Co (NYSE: LLY) CEO David Ricks told the Detroit Economic Club Thursday. The pharma...